Semaglutide — the GLP-1 mono-agonist, explained
Semaglutide (developed by Novo Nordisk, marketed as Ozempic for T2D, Wegovy for obesity, and Rybelsus as the oral version) is a synthetic 31-amino-acid peptide modeled on native GLP-1 with structural modifications that extend its half-life to approximately 165 hours (~one week). It was approved by the FDA in 2017 for type 2 diabetes and in 2021 for chronic weight management, and it has become the reference point against which tirzepatide, retatrutide, and every newer incretin compound is compared. This primer covers the molecule, the mechanism, the published trial programs, dose titration, the oral formulation, and why semaglutide remains the baseline in research and clinical discourse.
The molecule. Semaglutide's backbone is native human GLP-1(7-37) with two engineered substitutions: Aib (2-aminoisobutyric acid) at position 8 to resist DPP-4 degradation, and a C18 fatty diacid chain attached via a γGlu-2xOEG linker to Lys26 to enable albumin binding and extend the half-life. Molecular weight is approximately 4113.6 Da. The albumin-binding strategy is the same conceptual approach Lilly used for tirzepatide and retatrutide — semaglutide demonstrated the approach works and tirzepatide extended it to dual-agonism.
Mechanism, briefly. Semaglutide is a selective GLP-1 receptor agonist. On the GLP-1R, it triggers glucose-dependent insulin secretion from pancreatic β-cells (so hypoglycemia risk is low), suppresses glucagon secretion from α-cells, slows gastric emptying, and produces centrally-mediated satiety via action on arcuate-nucleus and brainstem neurons. Because semaglutide engages only the GLP-1R, it is the cleanest mono-agonist experimental tool in the class — useful when research protocols need to isolate GLP-1R effects from GIPR or GCGR contributions.
The SUSTAIN program (type 2 diabetes). The SUSTAIN-1 through SUSTAIN-10 phase III trials established semaglutide's efficacy in T2D. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260 is the foundational paper. For the head-to-head comparison data that matters for research positioning, Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinol. 2018;6(4):275-286 established semaglutide's superiority over the other once-weekly GLP-1 in the market.
The STEP program (obesity). The obesity indication data comes from the STEP-1 through STEP-8 trials. The landmark paper is Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002 (doi: 10.1056/NEJMoa2032183). STEP-1 showed approximately 15% body weight reduction at 68 weeks with semaglutide 2.4 mg weekly vs 2.4% for placebo. This is the number that anchors all subsequent GLP-1-class weight comparisons — tirzepatide's ~21% and retatrutide's ~24% are both expressed as multiples of the semaglutide baseline.
Oral vs injectable. Semaglutide is the first GLP-1 with a clinically effective oral formulation — Rybelsus, approved 2019 — using an absorption-enhancer technology (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to protect the peptide through the stomach and increase gastric absorption. Bioavailability from the oral form is low (~1%) and highly variable, which is why oral doses are 3-14 mg daily vs 0.5-2.4 mg weekly for injectable. In a research context, the injectable pen format is the cleaner pharmacokinetic tool; oral formulation is useful when studying the absorption-enhancer technology specifically.
Dose titration in published protocols. The approved titration for injectable semaglutide is 0.25 mg weekly for 4 weeks (not a therapeutic dose — tolerability building), then 0.5 mg for 4 weeks, then step to 1.0, 1.7, and 2.4 mg at 4-week intervals. For obesity, 2.4 mg weekly is the target dose. For T2D, 1.0 mg is often sufficient. GI tolerability (nausea, diarrhea) is the dominant practical constraint and the reason the titration schedule is slow. Research protocols should mirror this schedule unless specifically studying rapid-titration tolerability.
Comparative context. The GLP-1 family has three generations in active clinical use: mono-agonists (semaglutide, liraglutide, dulaglutide, exenatide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/GCGR (retatrutide, in phase III as of 2025). Semaglutide is the most-cited mono-agonist and the reference for all comparisons. Tirzepatide's ~1.4× weight-effect advantage and retatrutide's ~1.7× are both expressed relative to semaglutide. Semaglutide's commercial success also means it has the largest published real-world evidence dataset, which is useful for researchers designing protocols that need population-level comparators.
Storage, stability, and handling. Semaglutide in a prefilled pen is stable at 2–8 °C through the labeled expiry date. Once in use, the pen is stable for approximately 56 days at 2–8 °C or 28 days at room temperature (Novo Nordisk's Ozempic labeling) — this is longer in-use stability than most GLP-1-class compounds, which is one reason semaglutide became commercially dominant. Do not freeze; protect from light. The pen format sidesteps the contamination risk of open-vial reconstitution.
What the COA should say. A batch-specific COA for semaglutide should include (1) identity confirmation by HPLC-MS against the theoretical mass of approximately 4113.6 Da, (2) purity by reverse-phase HPLC-UV at 214 nm ≥ 98.0%, (3) residual solvent profile per ICH Q3C, (4) endotoxin by LAL in EU/mg. The C18 fatty diacid modification at Lys26 is a synthesis yield-critical step and the source of most purity losses — a purity chromatogram with shoulder peaks near the main peak often indicates unmodified or partially-modified semaglutide variants, which should be quantified on the COA if present.
Research-use only. Vivaprime supplies semaglutide as research reference material for qualified researchers engaged in in-vitro laboratory work. Although semaglutide has FDA approval as a therapeutic (Ozempic for T2D, Wegovy for obesity, Rybelsus oral) through Novo Nordisk, the material supplied here is not the FDA-approved pharmaceutical and is not supplied with the pharmaceutical-grade release documentation required for clinical or patient-facing use. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout.